Page 101 - 《中国药房》2022年16期

[11] RAHMAN M M，MCFADDEN G. Modulation of tumor compared to rheumatoid arthritis patients probably relates
necrosis factor by microbial pathogens[J]. PLoS Pathog， to disease-related factors[J]. J Eur Acad Dermatol Venereol，
2006，2（2）：e4. 2015，29（4）：752-760.
[12] KALB R E，FIORENTINO D F，LEBWOHL M G，et al. [19] SATOR P. Safety and tolerability of adalimumab for the
Risk of serious infection with biologic and systemic treat- treatment of psoriasis：a review summarizing 15 years of
ment of psoriasis：results from the psoriasis longitudinal real-life experience[J]. Ther Adv Chronic Dis，2018，9（8）：
assessment and registry（PSOLAR）[J]. JAMA Dermatol， 147-158.
2015，151（9）：961-969. [20] MULLER M，D’AMICO F，BONOVAS S，et al. TNF
[13] BURMESTER G R，PANACCIONE R，GORDON K B， inhibitors and risk of malignancy in patients with inflamma-
et al. Adalimumab：long-term safety in 23 458 patients tory bowel diseases：a systematic review[J]. J Crohns
from global clinical trials in rheumatoid arthritis，juvenile Colitis，2021，15（5）：840-859.
idiopathic arthritis， ankylosing spondylitis， psoriatic [21] KEMANETZOGLOU E，ANDREADOU E. CNS demye-
arthritis，psoriasis and Crohn’s disease[J]. Ann Rheum lination with TNF-α blockers[J]. Curr Neurol Neurosci
Dis，2013，72（4）：517-524. Rep，2017，17（4）：36.
[14] DIXON W G，HYRICH K L，WATSON K D，et al. Drug- [22] DING T N，LEDINGHAM J，LUQMANI R，et al. BSR
specific risk of tuberculosis in patients with rheumatoid and BHPR rheumatoid arthritis guidelines on safety of
arthritis treated with anti-TNF therapy：results from the anti-TNF therapies[J]. Rheumatology（Oxford），2010，49
British Society for Rheumatology Biologics Register （11）：2217-2219.
（BSRBR）[J]. Ann Rheum Dis，2010，69（3）：522-528. [23] SCHEINFELD N. Menorrhagia and severe menstrual pain
[15] GUINARD E，BULAI LIVIDEANU C，BARTHÉLÉMY related to the use of adalimumab in a psoriatic[J]. J Der-
H，et al. Active tuberculosis in psoriasis patients treated matolog Treat，2008，19（3）：188-189.
with TNF antagonists：a French nationwide retrospective [24] GREENWALD M W，SHERGY W J，KAINE J L，et al.
study[J]. J Eur Acad Dermatol Venereol，2016，30（8）： Evaluation of the safety of rituximab in combination with
1336-1341. a tumor necrosis factor inhibitor and methotrexate in
[16] KEANE J，GERSHON S，WISE R P，et al. Tuberculosis patients with active rheumatoid arthritis：results from a
associated with infliximab，a tumor necrosis factor randomized controlled trial[J]. Arthritis Rheum，2011，63
alpha-neutralizing agent[J]. N Engl J Med，2001，345 （3）：622-632.
（15）：1098-1104. [25] BEHNES M，AKIN I，BORGGREFE M，et al. Effect of
[17] MANSOURI Y，GOLDENBERG G. Biologic safety in tumor necrosis factor inhibitor treatment on proximal
psoriasis：review of long-term safety data[J]. J Clin right coronary chronic total occlusion in a patient with
Aesthet Dermatol，2015，8（2）：30-42. rheumatoid arthritis[J]. Circulation，2015，131（4）：e26-
[18] VAN LÜMIG P P，MENTING S P，VANDEN REEK J e28.
M，et al. An increased risk of non-melanoma skin cancer （收稿日期：2022-04-22 修回日期：2022-07-14）
during TNF-inhibitor treatment in psoriasis patients （编辑：陈 宏）

（上接第2005页）
[23] KOUROUKIS T，WHITE D，KRUSE M，et al. Cost-utility ple myeloma patients ineligible for stem cell transplanta-
of bortezomib in induction treatment prior to autologous tion in China[J]. J Comp Eff Res，2019，8（12）：979-992.
stem-cell transplantation（ASCT）in previously untreated [26] National Comprehensive Cancer Network. NCCN Guide-
multiple myeloma patients in Canada[J]. Blood，2013，122 lines for patients multiple myeloma[EB/OL].[2022-03-04].
（21）：1735. https：//www.nccn.org/patients/guidelines/content/PDF/
[24] 吴灵珍，戴崇文，彭宏凌.多发性骨髓瘤日间病房管理模 myeloma-patient.pdf.
式的医疗成本探讨[J].中国医疗保险，2019（9）：56-60. （收稿日期：2022-03-31 修回日期：2022-07-13）
[25] LU J，CHEN W D. Cost-effectiveness of lenalidomide （编辑：孙 冰）
plus low-dose dexamethasone for newly diagnosed multi-

中国药房 2022年第33卷第16期 China Pharmacy 2022 Vol. 33 No. 16 ·2011 ·